Pharmaceutical News

RSS

Quintiles, SNUH announce clinical research partnership

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.

7 Oct 2010

Roche receives development and commercialization rights for danoprevir drug

InterMune, Inc. today announced that it has sold worldwide development and commercialization rights to danoprevir (also known as RG7227 or ITMN-191) to Hoffman-La Roche Inc. and F. Hoffman-La Roche Ltd. for $175 million in cash.

7 Oct 2010

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.

7 Oct 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

Raloxifene drug may be useful in treating kidney disease in women: Study

The osteoporosis drug raloxifene may be useful in treating kidney disease in women, suggests a new study led by Michal Melamed, M.D., M.H.S., assistant professor of medicine and epidemiology & population health at the Albert Einstein College of Medicine of Yeshiva University.

7 Oct 2010

FDA awards cooperative agreement to PAHO to develop information hub for medical products

The U.S. Food and Drug Administration today announced the award of a $904,000 cooperative agreement to the Pan American Health Organization (PAHO) to research and develop an information hub for medical products and related regulatory processes and systems in the Americas Region.

7 Oct 2010

BioNJ creates special diagnostics committee to focus on personalized medicine

The strength of New Jersey's life sciences community and its unique ability to contribute to one of medicine's fastest growing areas—personalized medicine—has prompted BioNJ, the voice of the biotechnology industry in New Jersey, to create a special Diagnostics Committee.

7 Oct 2010

FDA unveils report to advance regulatory science

The U.S. Food and Drug Administration today unveiled a report outlining the agency's plans to advance regulatory science through its Regulatory Science Initiatie.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

CoreLab Partners completes first ever regulatory mandated Thorough QT study in the Asia Pacific Rim

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).

6 Oct 2010

Ibuprofen provides pain relief within two hours in 49% of migraine sufferers

For many people suffering from migraine headaches, over-the-counter ibuprofen - Advil and Motrin are well-known brands - might be enough to relieve the pain.

6 Oct 2010

Research to focus on effective use of artemisinin stocks for malaria

The frontline malaria treatment artemisinin could soon be treating more people for less cost, thanks to a research collaboration between Bradford and Shanghai.

6 Oct 2010

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Miller-McCune examines the limited access populations living in Africa have to the schistosomiasis drug praziquantel the only commercially available treatment for the disease.

6 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Study on resistance of harmful bacteria to antibiotics

A study by two Florida State University biochemists makes an important contribution to science's understanding of a serious problem causing concern worldwide: the growing resistance of some harmful bacteria to the drugs that were intended to kill them.

6 Oct 2010

New Wipro Rapid Trials platform launched to accelerate drug development

Wipro Technologies, the global Consulting, System Integration and Outsourcing business of Wipro Limited, today announced the launch of Wipro Rapid Trials platform to accelerate drug development across the globe.

6 Oct 2010

Anticancer drug Cisplatin induces side effects

Cisplatin, an anticancer drug widely used for treating various types of tumor, can induce side effects in the short term. A team of scientists, mostly from CNRS and the Université de Nice has provided first in vitro evidence that this antitumor agent modifies the sensitivity of cellular pressure sensors. This completely novel mechanism could help to elucidate certain neurological side effects of cisplatin hitherto unexplained.

6 Oct 2010

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.

6 Oct 2010

CDC grant to support community-based public health project in RI and CT

A $250,000 grant from the Centers for Disease Control and Prevention (CDC) will support a Rhode Island Hospital research study aimed at reducing the state's leading cause of accidental death among adults. Researchers will explore the use and effectiveness of statewide prescription monitoring programs (PMP) in reducing the number of accidental overdose deaths involving prescription opioids like OxyContin and Vicodin in both Rhode Island and Connecticut.

6 Oct 2010